RESOMER® RG 653 H is a bioresorbable poly(D,L-lactide-co-glycolide) 65:35 copolymer with acid-terminated end groups, supplied as white to off-white cylindrical granules for the manufacture of sustained-release parenteral dosage forms and implantable drug delivery systems. The grade designation identifies a 65:35 molar ratio of D,L-lactide to glycolide and a terminal carboxylic acid architecture. The copolymer is released against an inherent viscosity specification of 0.32–0.44 dL/g measured in chloroform at 25 °C at 0.1% w/v using capillary viscometry. The acid value is lot-specific and is determined by titration; this parameter serves as a practical indicator of free carboxyl end-group density.

Batch documentation includes residual D,L-lactide, residual glycolide, residual solvent, water content, tin catalyst residues, heavy metals, and sulfated ash where applicable. Storage in sealed containers at −20 °C or below is recommended; containers should be equilibrated to ambient temperature before opening to prevent condensation. At relative humidity above 60%, the granule surface can adsorb sufficient water to reduce molecular weight during subsequent hot-melt processing or storage. The polymer is soluble in dichloromethane, chloroform, acetone, and tetrahydrofuran; it is not soluble in water, ethanol, or aliphatic hydrocarbon solvents.

The matrix summarises the most commonly cited specification windows in supplier technical documentation; the certificate of analysis for each lot remains the binding document.

In research and development, number-average molecular weight and weight-average molecular weight are determined by gel permeation chromatography with refractive index and multi-angle laser light scattering detection. The use of light scattering permits absolute molecular weight determination without relying solely on polystyrene calibrants. The acid number is determined by dissolving the polymer in a suitable solvent and titrating with methanolic potassium hydroxide; the result is expressed in milligrams of potassium hydroxide per gram. Because the acid value is inversely related to number-average molecular weight for linear acid-terminated chains, it can be used as a secondary process control parameter. The polydispersity index of RG 653 H is not normally a release specification but is reported in some research studies; values observed in commercial biodegradable polyesters of this molecular weight range often fall between 1.5 and 2.5, though lot-specific measurements may be narrower or wider. Published data for this specific grade is limited.

How does terminal carboxyl content alter the microsphere hardening window?

In solvent-evaporation microsphere manufacture, RG 653 H is dissolved in dichloromethane at a polymer concentration from 5% to 20% w/w. The organic phase is dispersed into an aqueous continuous phase containing poly(vinyl alcohol), often with a high-shear rotor–stator mixer. The acid-terminated end groups raise the overall hydrophilicity relative to an ester-terminated 65:35 PLGA of similar molecular weight. During solvent removal, water from the continuous phase partitions into the forming microspheres and lowers the glass transition temperature; if the matrix remains below 25 °C during solvent stripping, microsphere coalescence and surface pitting may occur. The process therefore requires controlled solvent removal, often by reduced pressure or stirred extraction, with gel permeation chromatography monitoring of molecular weight before and after the emulsification step. Accepted in vitro release testing for microspheres prepared from this grade is performed using flow-through cells or paddle apparatus under USP 4 or USP 2; the choice of release medium must be justified because the polymer is hydrolytically degraded by phosphate-buffered saline at 37 °C and the resulting carboxylic acid generation can lower the local pH within the matrix. This microclimate can influence acid-labile actives and peptide stability. Published data for RG 653 H in this specific emulsion configuration is limited; process development is therefore conducted with batch-to-batch viscosity and acid value data as covariates.

For hot-melt extrusion or compression molding, the granulate is dried under vacuum or dry-air purge at temperatures below the glass transition, normally 25–40 °C, until the Karl Fischer water content is below 0.5%. Drying above the glass transition risks granule agglomeration and particle fusion in the hopper. Extrusion is carried out at temperatures above the glass transition and below the degradation onset; the barrel profile must be established per lot because residual monomers and terminal acid groups reduce the thermal stability of the melt. The glass transition of RG 653 H is reported by differential scanning calorimetry per ISO 11357-2 in the range 44–50 °C. Loss-on-drying and melt flow index are not normally used as release specifications for this medical-grade copolymer; molecular weight stability during melt processing is better followed by gel permeation chromatography with refractive index detection after sampling the extrudate at start-up, mid-run, and shutdown.

In solvent-based coating or nanoparticle processes, the acid-terminated copolymer can interact with cationic surfactants or cationic lipophilic actives. During emulsification, the presence of free acid groups affects the surface charge of the organic phase; at pH values above the apparent pKa of the polymer chain ends, the interface becomes more negative, which can stabilize the emulsion but also attract cationic species from the continuous phase. This effect is exploited in some formulations but causes batch-to-batch variation if the acid value drifts within the specified range. Zeta potential measurements with dynamic light scattering can be used to track this interaction. Ethyl acetate has been evaluated as a less toxic alternative to dichloromethane in biodegradable microsphere production; however, the solubility of RG 653 H in ethyl acetate is lower than in dichloromethane and requires longer solvent removal times. Residual solvent in the finished microspheres must satisfy ICH Q3C limits for dichloromethane or ethyl acetate.

Residual monomer and tin residue thresholds under terminal sterilization

Gamma irradiation and ethylene oxide sterilization introduce additional constraints. RG 653 H is not supplied sterile; terminal sterilization must be validated for the finished drug product. Gamma irradiation can reduce molecular weight and increase carboxylic acid end groups by chain scission; the extent depends on dose, temperature, and moisture. Doses from 15 kGy to 25 kGy are common for microbiological safety, but the polymer molecular weight loss at these doses can shift release kinetics. If steam sterilization is used, hydrolytic degradation occurs rapidly at temperatures above the glass transition; this route is generally incompatible with the bulk polymer. Ethylene oxide may be retained in the matrix and requires aeration studies according to ISO 10993-7; residual ethylene oxide and ethylene chlorohydrin limits are set for the finished device. Residual monomer data from the supplier is relevant because D,L-lactide and glycolide are hydrolysis products and potential leachables. When the certificate of analysis reports monomer levels above 0.5%, the melt-processing window narrows due to plasticization and accelerated degradation. Published data for RG 653 H under gamma sterilization specifically is limited; polymer suppliers often provide dose-response data under confidentiality agreements.

When replacing ester-terminated PLGA grades in solvent-evaporation and twin-screw lines

Replacement of an ester-terminated PLGA with RG 653 H is not a like-for-like substitution. The free carboxylic acid groups increase acid value and can interact with amine-containing APIs, protonate weakly basic actives, or adsorb peptides and proteins at the particle surface. Such interactions may change encapsulation efficiency and initial release relative to an ester-terminated 65:35 PLGA. A comparative program should include acid value titration, gel permeation chromatography, and in vitro release testing under one defined method; USP 4 flow-through cells provide sink conditions for low-solubility actives and avoid particle aggregation artefacts that may occur in paddle vessels. Relative to 50:50 PLGA grades such as RG 502 H or RG 503 H, the 65:35 lactide-rich backbone of RG 653 H contains less glycolide and is generally associated with slower hydrolysis at neutral pH, because glycolide units are more hydrophilic and degrade more rapidly than lactide units. Compared with 75:25 PLGA grades, RG 653 H has higher glycolide content and is generally expected to hydrate and mass-lose more rapidly. The exact rank order depends on molecular weight, sterilization dose, implant geometry, and the pH of the in vitro medium. Published data for all three grades in a single standardized release model is limited; direct comparative studies should use identical organic solvent, emulsifier, and residual moisture levels to avoid confounding.

In vitro hydrolysis of PLGA proceeds by ester bond cleavage with bulk erosion. The 65:35 copolymer initially absorbs water and undergoes hydrolysis of glycolide-rich domains; lactic acid and glycolic acid are formed. The terminal carboxylic acid groups in RG 653 H accelerate the initiation of hydrolysis because they create a more acidic microenvironment at chain ends. Molecular weight loss is commonly monitored by gel permeation chromatography with tetrahydrofuran or chloroform as eluent. Mass loss follows molecular weight loss with a lag phase; oligomers and monomers become soluble and diffuse from the matrix when their molecular weight falls below a threshold. The degradation rate depends on temperature, medium pH, and device geometry; standardized in vitro degradation studies use phosphate-buffered saline at 37 °C and pH 7.4, but phosphate buffers can accelerate degradation relative to physiological conditions by increasing the buffer capacity.

Aseptic filtration of polymer solutions through 0.22 µm membranes is used for sterile microsphere processes, but the solution viscosity at the chosen solvent and concentration must be within the membrane cassette throughput limits. Terminal sterilization of the bulk polymer is not a substitute for sterile filtration of the drug-loaded product. The supplier provides regulatory support documentation and the certificate of analysis; the finished dosage form developer remains responsible for compendial compliance under FDA 21 CFR Part 211, ICH Q3C residual solvent limits, and the applicable pharmacopoeial monograph for the drug product.